Efficacy of adding Luvos® Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial

Introduction: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. Treatment can improve symptoms and social functioning in the patients. This study was designed to assess the effect of adding Luvos supplementation to mebeverine on improving symptoms and quality of life (QOL) in patients with diarrhea-predominant irritable bowel syndrome. Methods: Eighty patients with diarrhea-predominant IB, ages 18-65, were diagnosed by the Rome IV criteria and randomly assigned to the study. Forty patients (group A) received mebeverine (135 mg) twice a day (bid) plus Luvos®Healing Earth (1 sachet, bid). The other 41 patients (group B) received mebeverine (135 mg) bid for 4 weeks. Basic demographic data, Bristol score, symptom severity score, and QOL questionnaire were recorded at the start and completion of treatment. The data were analyzed by SPSS version 22. Results: Seventy one of the patients (35 and 36 patients in groups A and B, respectively) completed the study. The majority of the patients were young males, unmarried and highly educated. Diarrhea and QOL were both significantly improved in group A when compared to group B (P=0.036 and P=0.028, respectively). We did not find a significant difference (improvement) in abdominal pain or overall symptom score between group A (mebeverine + Luvos) compared to group B (mebeverine alone) (P=0.096 and P=0.071, respectively). Mild and tolerable adverse effects were observed in 2.8% (2/71) of the patients. Conclusion: According to our results, Luvos supplementation is safe, effective and well-tolerated in diarrhea-predominant irritable bowel syndrome patients. Further study with a larger sample size is recommended to evaluate the efficacy of this natural clay-like medicine.

[1]  S. Hollon,et al.  Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. , 2017, Clinical psychology review.

[2]  Lin Chang,et al.  Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice , 2017, Therapeutic advances in gastroenterology.

[3]  R. Arbuckle,et al.  Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log , 2016, Quality of Life Research.

[4]  J. Fichna,et al.  Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome , 2016, Therapeutics and clinical risk management.

[5]  M. Khorram,et al.  Efficacy of Iranian and foreign mebeverine on IBS patients with diarrhea attending to gastroenterology clinic of Amir-Al-Momenin between 2009 and 2013 , 2016 .

[6]  A. Foxx-Orenstein.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists , 2016, Therapeutic advances in gastroenterology.

[7]  J. Thompson.  Is irritable bowel syndrome an infectious disease? , 2016, World journal of gastroenterology.

[8]  Q. Pan,et al.  A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea‐Predominant Irritable Bowel Syndrome , 2015, Phytotherapy research : PTR.

[9]  P. Moayyedi,et al.  Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.

[10]  P. Marquis,et al.  Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome , 2014, Clinical and Translational Gastroenterology.

[11]  T. Wittmann,et al.  Role of antispasmodics in the treatment of irritable bowel syndrome. , 2014, World journal of gastroenterology.

[12]  F. Bosques-Padilla,et al.  Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. , 2012, Revista de gastroenterologia de Mexico.

[13]  C. Sohn,et al.  Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[14]  H. Fathy,et al.  Quality of Life: The Ultimate Outcome Measure of Interventions in Major Depressive Disorder , 2011, Harvard review of psychiatry.

[15]  박효진.  Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine , 2011 .

[16]  Z. Farajzadegan,et al.  Linguistic validation of the Irritable Bowel Syndrome-Quality of Life Questionnaire for Iranian patients. , 2011, Acta medica Iranica.

[17]  Wei Bo Li,et al.  Solubility of uranium and thorium from a healing earth in synthetic gut fluids: a case study for use in dose assessments. , 2010, The Science of the total environment.

[18]  S. Nikfar,et al.  A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. , 2010, World journal of gastroenterology.

[19]  F. Chang,et al.  Treatment of Irritable Bowel Syndrome Using Complementary and Alternative Medicine , 2009, Journal of the Chinese Medical Association : JCMA.

[20]  E. Quigley,et al.  Irritable bowel syndrome: recent progress in pathophysiology, diagnosis and management? , 2009, Journal of Ayub Medical College, Abbottabad : JAMC.

[21]  Edu,et al.  Bmc Complementary and Alternative Medicine Complementary and Alternative Medicine Use and Cost in Functional Bowel Disorders: a Six Month Prospective Study in a Large Hmo , 2022 .

[22]  J. Sung,et al.  Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. , 2006, Journal of alternative and complementary medicine.

[23]  S. Willich,et al.  Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease , 2006, BMC complementary and alternative medicine.

[24]  E. Quigley,et al.  Systematic review: complementary and alternative medicine in the irritable bowel syndrome , 2006, Alimentary pharmacology & therapeutics.

[25]  N. Talley,et al.  Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia , 2003, Alimentary pharmacology & therapeutics.